SFAM
CYTK icon

Springhill Fund Asset Management’s Cytokinetics CYTK Stock Holding History

Springhill Fund Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-130,735
Closed -$6.15M – 24
2024
Q4 		$6.15M Buy
+130,735
New +$6.79M 9.99% 3

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Springhill Fund Asset Management's CYTK Position: Q1 2025 in Review

Springhill Fund Asset Management sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 130,735 shares — an estimated $6.15M sold.

Springhill Fund Asset Management first reported a position in CYTK in Q4 2024 and held it in 1 quarter. The position peaked at $6.15M in Q4 2024. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • Springhill Fund Asset Management reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
  • Springhill Fund Asset Management sold 130,735 Cytokinetics shares in Q1 2025, an estimated $6.15M.
  • Springhill Fund Asset Management first reported a position in Cytokinetics in Q4 2024 and held it in 1 quarter.
  • Springhill Fund Asset Management's Cytokinetics position peaked at $6.15M in Q4 2024.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on Springhill Fund Asset Management's 13F filing for Q1 2025, filed 14 May 2025.